http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#head http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw http://www.nanopub.org/nschema#hasAssertion http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#assertion http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw http://www.nanopub.org/nschema#hasProvenance http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#provenance http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw http://www.nanopub.org/nschema#hasPublicationInfo http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#publicationInfo http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#assertion http://bio2rdf.org/drugbank:DB00195 http://bio2rdf.org/drugbank_vocabulary:ddi-interactor-in http://bio2rdf.org/drugbank_resource:DB00195_DB00457 http://bio2rdf.org/drugbank:DB00457 http://bio2rdf.org/drugbank_vocabulary:ddi-interactor-in http://bio2rdf.org/drugbank_resource:DB00195_DB00457 http://bio2rdf.org/drugbank_resource:DB00195_DB00457 http://purl.org/dc/terms/identifier drugbank_resource:DB00195_DB00457 http://bio2rdf.org/drugbank_resource:DB00195_DB00457 http://purl.org/dc/terms/title DDI between Betaxolol and Prazosin - Beta-Blockers such as betaxolol may enhance the orthostatic hypotensive effect of Alpha1-Blockers such as prazosin. The risk associated with ophthalmic products is probably less than systemic products. Exercise caution if an alpha1-blocker is added to existing beta-blocker therapy. Monitor for hypotension during first few days of concomitant therapy. A priori reduction in alpha1-blocker (especially systemic) dose may be warranted. Administering the first dose of systemic agents at bedtime may help minimize risk of severe hypotension. The risk associated with the use of ophthalmic products in either interacting group is probably less than that associated with systemic agents. If the alpha1-blocker is being used to treat BPH, consider using tamsulosin since its alpha1-A selectivity is least likely to cause hypotension. http://bio2rdf.org/drugbank_resource:DB00195_DB00457 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://bio2rdf.org/drugbank_vocabulary:Drug-Drug-Interaction http://bio2rdf.org/drugbank_resource:DB00195_DB00457 http://www.w3.org/2000/01/rdf-schema#label DDI between Betaxolol and Prazosin - Beta-Blockers such as betaxolol may enhance the orthostatic hypotensive effect of Alpha1-Blockers such as prazosin. The risk associated with ophthalmic products is probably less than systemic products. Exercise caution if an alpha1-blocker is added to existing beta-blocker therapy. Monitor for hypotension during first few days of concomitant therapy. A priori reduction in alpha1-blocker (especially systemic) dose may be warranted. Administering the first dose of systemic agents at bedtime may help minimize risk of severe hypotension. The risk associated with the use of ophthalmic products in either interacting group is probably less than that associated with systemic agents. If the alpha1-blocker is being used to treat BPH, consider using tamsulosin since its alpha1-A selectivity is least likely to cause hypotension. [drugbank_resource:DB00195_DB00457] http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#provenance http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#assertion http://semanticscience.org/resource/SIO_000253 http://bio2rdf.org/drugbank_resource:bio2rdf.dataset.drugbank.R3 http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#publicationInfo http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#signature.MC0CFQCWKxFdkb1T http://purl.org/nanopub/x/hasPublicKey MIIBtzCCASwGByqGSM44BAEwggEfAoGBAP1/U4EddRIpUt9KnC7s5Of2EbdSPO9EAMMeP4C2USZpRV1AIlH7WT2NWPq/xfW6MPbLm1Vs14E7gB00b/JmYLdrmVClpJ+f6AR7ECLCT7up1/63xhv4O1fnxqimFQ8E+4P208UewwI1VBNaFpEy9nXzrith1yrv8iIDGZ3RSAHHAhUAl2BQjxUjC8yykrmCouuEC/BYHPUCgYEA9+GghdabPd7LvKtcNrhXuXmUr7v6OuqC+VdMCz0HgmdRWVeOutRZT+ZxBxCBgLRJFnEj6EwoFhO3zwkyjMim4TwWeotUfI0o4KOuHiuzpnWRbqN/C/ohNWLx+2J6ASQ7zKTxvqhRkImog9/hWuWfBpKLZl6Ae1UlZAFMO/7PSSoDgYQAAoGAETGrDm8R3KfndKRj7ttr3jVhhstI6/2Ey0ER9F5kdx7Hrd6eolq7yWzPzf2H754tdZxICzxYcdawBbL2ZUzFjWwXTNUQC3+e6evKPJyNELubnZcA+8TxIIwicBnw3Ku6mSeI8SUVr5SBV1VeJoSu/ahldv562IdBR8IagmzuT3Y= http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#signature.MC0CFQCWKxFdkb1T http://purl.org/nanopub/x/hasSignature MC0CFQCWKxFdkb1TJe/Dn2XFQjZb65V5+gIUTrr+qSCG9XHwPL9KS64zrAlKrEA= http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#signature.MC0CFQCWKxFdkb1T http://purl.org/nanopub/x/signedBy https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw http://purl.org/dc/terms/created 2018-03-30T11:12:51.993+02:00 http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw http://purl.org/dc/terms/license https://creativecommons.org/licenses/by-nc/4.0/ http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw http://purl.org/nanopub/x/hasSignatureElement http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw#signature.MC0CFQCWKxFdkb1T http://bio2rdf.org/drugbank_resource:DB00195_DB00457_nanopub.RA7WGhyjBZWXVwbIKPyqzv9cURHubMFpdI6a5iykvTOSw http://www.w3.org/ns/prov#wasGeneratedBy https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://www.w3.org/ns/prov#specializationOf https://github.com/tkuhn/bio2rdf2nanopub https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://www.w3.org/ns/prov#wasAttributedTo http://orcid.org/0000-0002-1267-0234 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://purl.org/dc/terms/identifier 3c184e6c-ceb8-4275-a679-71dfbdac2a11 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://www.w3.org/ns/prov#used https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://www.w3.org/ns/prov#wasAssociatedWith https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://www.w3.org/ns/prov#wasStartedBy http://orcid.org/0000-0002-1267-0234 https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://purl.org/dc/terms/isVersionOf https://github.com/tkuhn/bio2rdf2nanopub https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://purl.org/pav/version eda7951a5f6c622c5d2132f50c3093138484a349 https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://www.w3.org/ns/prov#wasAttributedTo http://orcid.org/0000-0002-1267-0234